Methotrexate in systemic lupus erythematosus.

Walz LeBlanc, B A; Dagenais, P; Urowitz, M B; Gladman, D D

Walz LeBlanc, B A; Dagenais, P; Urowitz, M B; Gladman, D D.

Affiliation

Walz LeBlanc BA; Lupus Clinic, Wellesley Hospital, Toronto, ON, Canada.

J Rheumatol ; 21(5): 836-8, 1994 May.

Article in En | MEDLINE | ID: mdl-8064722

Subject(s)

Lupus Erythematosus, Systemic/drug therapy; Methotrexate/therapeutic use; Adolescent; Adult; Arthritis/drug therapy; Arthritis/etiology; Female; Humans; Lupus Erythematosus, Systemic/complications; Lupus Nephritis/drug therapy; Lupus Nephritis/etiology; Retrospective Studies; Treatment Outcome

Search on Google

Add to My VHL

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Methotrexate / Lupus Erythematosus, Systemic Type of study: Etiology_studies / Observational_studies / Risk_factors_studies Limits: Adolescent / Adult / Female / Humans Language: En Journal: J Rheumatol Year: 1994 Document type: Article Affiliation country: Canada

Search on Google

Add to My VHL

XML

PubMed Links